美国30至45岁成人HPV疫苗接种的成本效果分析
该研究利用两个独立的HPV微模拟模型,评估将女性(从26岁)和男性(从21岁)的HPV疫苗接种年龄上限扩展至30、35、40或45岁的成本效果。模型基于美国HPV及相关癌症负担校准,结果显示接种至45岁的增量成本效果比(ICER)为每获得一个质量调整生命年(QALY)315,700至440,600美元,高于常用的20万美元/QALY上限。结论认为,在美国,30至45岁成人接种HPV疫苗不太可能具有成本效益。
要点
- 将HPV疫苗接种年龄上限提高至45岁,成本增加但健康收益也增加。
- 接种至45岁的ICER为315,700–440,600美元/QALY,超过20万美元/QALY的常用阈值。
- 接种至30、35、40岁的策略成本效果均低于接种至45岁。
核心结论
- 基于两个独立模型,美国30至45岁成人接种HPV疫苗不太可能具有成本效益。
研究设计与样本
- 使用两个独立的HPV微模拟模型,评估将女性(从26岁)和男性(从21岁)接种年龄上限扩展至30、35、40或45岁的成本效果。
- 模型根据美国HPV及相关癌症负担进行实证校准,采用关于历史与未来接种率、疫苗效力、宫颈癌筛查和成本的标准化输入。
主要发现
- 两个模型均预测,随着接种年龄上限提高,成本增加且健康收益增加。
- 接种女性及男性至30、35、40岁的策略成本效果低于接种至45岁。
- 接种至45岁的ICER超过常用的20万美元/QALY上限;纳入所有HPV相关结局时,ICER为315,700至440,600美元/QALY。
关键数值与推荐
- 接种至45岁的ICER范围为315,700至440,600美元/QALY(纳入所有HPV相关结局)。
- 常用成本效果阈值为20万美元/QALY。
临床怎么用
- 在美国,将HPV疫苗接种年龄上限扩展至30至45岁可能不符合成本效果原则。
- 决策时需考虑宫颈筛查依从性、疫苗成本和非宫颈HPV相关癌症自然史的影响。
局限性
- 模型数据存在不确定性,包括疫苗对非宫颈癌症影响的时间及对较年长者的疫苗效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A nonavalent human papillomavirus (HPV) vaccine has been licensed for use in women and men up to age 45 years in the United States. The cost-effectiveness of HPV vaccination for women and men aged 30 to 45 years in the context of cervical cancer screening practice was evaluated to inform national guidelines. METHODS AND FINDINGS: We utilized 2 independent HPV microsimulation models to evaluate the cost-effectiveness of extending the upper age limit of HPV vaccination in women (from age 26 years) and men (from age 21 years) up to age 30, 35, 40, or 45 years. The models were empirically calibrated to reflect the burden of HPV and related cancers in the US population and used standardized inputs regarding historical and future vaccination uptake, vaccine efficacy, cervical cancer screening, and costs. Disease outcomes included cervical, anal, oropharyngeal, vulvar, vaginal, and penile cancers, as well as genital warts. Both models projected higher costs and greater health benefits as the upper age limit of HPV vaccination increased. Strategies of vaccinating females and males up to ages 30, 35, and 40 years were found to be less cost-effective than vaccinating up to age 45 years, which had an incremental cost-effectiveness ratio (ICER) greater than a commonly accepted upper threshold of $200,000 per quality-adjusted life year (QALY) gained. When including all HPV-related outcomes, the ICER for vaccinating up to age 45 years ranged from $315,700 to $440,600 per QALY gained. Assumptions regarding cervical screening compliance, vaccine costs, and the natural history of noncervical HPV-related cancers had major impacts on the cost-effectiveness of the vaccination strategies. Key limitations of the study were related to uncertainties in the data used to inform the models, including the timing of vaccine impact on noncervical cancers and vaccine efficacy at older ages. CONCLUSIONS: Our results from 2 independent models suggest that HPV vaccination for adult women and men aged 30 to 45 years is unlikely to represent good value for money in the US.
引用
- Kim JJ, Simms KT, Killen J, et al. Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. PLoS Med. 2021. PMID: 33705382. doi:10.1371/journal.pmed.1003534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。